Partnerships & Mergers

The partnership reflects Upwyde Developments’ vision of creating smart, mixed-use destinations that integrate residential, commercial, administrative, and medical services in one location.

Nine countries now maintain consistently low measles incidence rates, reporting fewer than five cases per million residents.

By integrating Aicuris into its global development and commercialization infrastructure, Asahi Kasei accelerates its expansion in the specialty pharmaceutical sector.

The agreement also includes potential clinical, regulatory, and commercial milestone payments that could raise the total value to USD7 billion,

Biogen now holds worldwide rights to the investigational therapy, felzartamab, which is currently undergoing Phase 3 clinical trials for several immune-mediated diseases.

The Phase Ib/II trial will assess safety, tolerability, and early signs of clinical activity. Researchers will combine Boehringer Ingelheim’s investigational T-cell engager, obrixtamig, with Zai Lab’s antibody-drug conjugate (ADC), zocilurtatug pelitecan (zoci).

The partnership leverages the EAEA’s scientific expertise with Alameda Healthcare’s clinical and operational capabilities to create a sustainable, patient-centered treatment hub.

The collaboration leverages JW Pharmaceutical’s established research and development capabilities to accelerate the drug’s entry into South Korea’s growing metabolic disease sector.

Through this agreement, Gilead now controls global rights to KT-200, an oral CDK2 molecular glue degrader designed to treat cancer.

AVS has developed the Pulse IVL system, which uses pressurised sound waves delivered through a balloon catheter to remove calcium deposits in patients with calcified peripheral artery disease (PAD).